The purpose of this report is to describe the tolerability and poside at 1200 mg/m 2 , in children with relapsed and refracactivity of the combination of high-dose cytosine arabinoside tory acute leukemias. Ara-C, daunorubicin, etoposide, thioguanine and dexame-
thasone (DCTER), utilized by the Children's Cancer Group (CCG). 10 A fifth child with relapsed ANLL had failed reinduction with '7 and 3' (Ara-C and daunorubicin) therapy. Two of the five refractory ANLL patients had a cytogenetic abnorIntroduction mality in their leukemic blasts (11q−, 7q−) associated with a poor response to chemotherapy and/or poor disease-free surThe majority of children with acute lymphocytic leukemia vival. 11 Two patients had ALL which relapsed following suc-(ALL) and acute nonlymphocytic leukemia (ANLL) treated with cessful initial induction therapy with anthracycline-based regimodern chemotherapeutic regimens enter a complete mens for high-risk patients and which were refractory to remission. 1, 2 For those children failing to enter remission, or reinduction with vincristine, prednisone, l-asparaginase and those relapsing following standard therapy, marrow-ablative daunorubicin (VPLD); one child had acute biphenotypic leutherapy with high-dose chemotherapy and total body kemia which had failed to respond to therapy for either ALL irradiation, followed by allogeneic bone marrow transplan-(VPLD) or ANLL (DCTER). tation (BMT) from an HLA-matched donor, has produced long-term durable remissions; [3] [4] [5] [6] however, the best results are obtained in those patients who attain remission prior to trans-HDAC/VP-16 as post-remission intensification therapy plantation. For patients without allogeneic bone marrow donors, the outlook is poor; intensive chemotherapeutic regiTen children received HDAC/VP-16 as post-remission intensimens or purged autologous bone marrow transplantation have fication therapy for relapsed, refractory or secondary acute resulted in long-term survival for only a minority of relapsed leukemias. Four patients with relapsed ALL (two with relapses patients (primarily children with ALL who experience a late while receiving a CCG modification of Berlin-Frankfurtrelapse after completing therapy). [7] [8] [9] New treatment regimens Munster (BFM) therapy for intermediate-and high-risk ALL which will improve both remission attainment and diseaseincluding a delayed intensification, 12 and two with relapses at free survival for these patients are needed. We describe our 41 and 51 months after diagnosis following completion of the experience with high-dose cytosine arabinoside given at the same therapy) were in second remission following VPLD reinmaximally tolerated dose (MTD) of 36 g/m 2 , together with etoduction therapy, as was a patient with lymphoblastic lymphoma who suffered a leukemic relapse while receiving intensive anthracycline-based lymphoma therapy. 13 No patient with refractory ALL or acute biphenotypic leukeAll patients developed fever; eight patients had positive blood cultures (four Staph. epidermitis, three Strep. viridans, mia attained a complete remission. All of these patients had a partial response with a reduction in bone marrow blasts.
one Klebsiella/Enterobacter, one E. coli, one Candida), and an additional two patients had radiologic evidence of invasive Clinical characteristics and outcomes of the eight children receiving HDAC/VP16 as salvage induction therapy are sumpulmonary fungal infections without positive blood cultures. Four patients developed grade 3-4 acral erythroderma followmarized in Table 1. ing treatment, with full thickness peeling of the palms and soles. Mucositis, conjunctivitis and diarrhea were common, but not severe (grades 1 and 2). One patient with a history of HDAC/VP-16 as post-remission intensification therapy prior CNS disease had cerebellar toxicity, which has partially resolved. All patients survived at least 45 days following the Five patients with ANLL and five patients with lymphoid malignancies received HDAC/VP-16 as post-remission intensiinitiation of therapy; there were no therapy-related deaths. fication therapy. Additional therapy following HDAC/VP-16 included matched unrelated donor BMT in two patients, purged autologous BMT in two patients, and maintenance Discussion therapy for ALL in three patients (daily oral 6-mercaptopurine, weekly oral methotrexate, and monthly vincristine/prednisone Cytosine arabinoside is an effective anti-leukemic agent with minimally toxic side-effects when used at conventional doses pulses with intrathecal methotrexate, with a modified BFM Table 2 Characteristics of patients receiving HDAC/VP-16 as post- Table 1 Characteristics and (6) synergy of Ara-C and etoposide against a murine leudisease-free survival when used as post-remission therapy in first remission of ANLL, [24] [25] [26] [27] [28] [29] including demonstration of a kemia model. 45 The combination of etoposide together with Ara-C given at dose-response effect when compared to lower doses of Ara-C in a large, multicenter randomized trial.
29 High-dose Ara-C either standard doses 46 or high doses [47] [48] [49] has been previously described in the treatment of relapsed and/or refractory acute administration during initial induction therapy for ANLL has also been associated with improved outcome compared to leukemia, with varying efficacy; however, only three other groups have employed Ara-C at the MTD of 36 g/m 2 in combistandard-dose Ara-C in a large, multicenter randomized trial, 30 again supporting the concept of a significant dosenation with etoposide. Gryn et al 50 treated 13 patients with relapsed or refractory myeloid leukemias with Ara-C (3 g/m 2 effect for Ara-C.
The improved efficacy of high-dose Ara-C therapy, as comq 12 h × 12 doses; 36 g/m 2 total) followed by etoposide (100 mg/m 2 q day 1× 3 days; 300 mg/m 2 total). Seven of nine pared to standard-dose therapy, results from the ability of high levels of drug to overcome decreased membrane and/or intrapatients with relapsed or refractory AML (78%) achieved CR. Significant toxicities consisted of grade 4 hematologic (100%), cellular transport, which may contribute to resistance to standard doses of Ara-C.
31-34 Most regimens employing high-dose grade 3 or 4 infection (100%), grade 3 neurologic (23%) and grade 3 dermatologic (15%) toxicities. The median time to Ara-C have used doses of 2-3 g/m 2 infused over 1-3 h, as this schedule has been shown to result in steady-state plasma con-ANC Ͼ500/mm 3 was 29 days and to platelet count Ͼ50 000 mm 3 was 27 days. Freund et al 51 treated 32 patients centrations in excess of 100 mol/l, 35 a level which is adequate to overcome the rate-limiting step of the transport with relapsed or refractory acute leukemia with Ara-C (3 g/m 2 q 12 h × 12 doses; 36 g/m 2 total) together with etopoprocess on Ara-CTP formation. High intracellular levels of Ara-CTP are predictive of response to high-dose Ara-C. 36 side (100 mg/m 2 q day × 5 days; 500 mg/m 2 total). Forty-six percent of patients with ANLL and 50% of patients with ALL Herzig et al 19 identified the maximum tolerated single dose (MTD) of Ara-C, when given at 12 h intervals, as 3 g/m 2 ; sevattained a CR. Grade 4 hematologic toxicity was again universal; the median time to ANC Ͼ500/mm 3 was 24 days and to ere CNS toxicity was dose-limiting above this level. The maximum duration of therapy at this dose level was 6 days; platelet count Ͼ20 000 mm 3 was 21 days. Other significant toxicities included grade 3 or 4 mucositis (31%) and grade 3 thus, the maximum tolerated regimen was 36 g/m 2 . Wolff et al 24 used this regimen of high-dose Ara-C at the MTD, together or 4 infection (28%). The Southeastern Cancer Study Group 52 conducted a ranwith daunomycin, as consolidation therapy for ANLL in first remission; the estimated proportion of patients remaining in domized clinical trial in 133 adult patients with relapsed and refractory ANLL comparing Ara-C (3 g/m 2 q 12 h × 12 doses; continuous CR was 49%. These results are among the best attained in ANLL without allogeneic BMT, and remain better 36 g/m 2 total) as a single agent vs this same Ara-C regimen followed by etoposide (100 mg/m 2 q day × 3 days; 300 mg/m 2 than more recently described regimens which utilize highdose Ara-C as post-remission therapy at less than the MTD. 29 total). Although there was no difference in overall survival of the two groups, those patients less than 50 years of age on A comparison of the results of these large clinical trials suggests added benefit for administration of an extended schedule the high-dose Ara-C + etoposide arm had a significantly longer survival than those on the high-dose Ara-C arm (P = 0.036). of Ara-C at 3 g/m 2 , although other factors such as patient selection may account for some of the difference. The major In addition, the median duration of remission was 11.9 months on the high-dose Ara-C arm and 25 months on the toxicity of the regimen utilizing 36 m/m 2 Ara-C together with an anthracycline was pancytopenia, with 5% toxic deaths durhigh-dose Ara-C + etoposide arm. There were no differences between the two regimens in regard to the frequency of all ing therapy; 5 the average duration of neutropenia (ANC Ͻ500) was 19 days (range , and average duration of thromgrades of toxic events, although patients on the high-dose Ara-C + etoposide arm did have significantly more grade III-IV bocytopenia (platelet count Ͻ20 000) was 20 days (range 7-150). Cerebellar dysfunction is the dose-limiting toxicity of mucositis and hepatocellular enzyme elevations. Unfortunately, data indicating median time to recovery of WBC and cytosine arabinoside; the overall incidence is approximately 8%. 37 Although patients over 50 years of age are at highest platelet counts for the two regimens were not provided in this report. risk for this complication, neurologic complications also have been described in children receiving high-dose Ara-C. 38 Other In conclusion, our results confirm previous reports demonstrating that the combination of high-dose Ara-C and etopotoxicities reported following high-dose Ara-C include pulmonary insufficiency syndromes 39, 40 and erythematous skin reacside is an effective salvage induction regimen, without anthracyclines or other cardiotoxic agents, for patients with relapsed tions 19 similar to that seen in our patients. We administered Ara-C at the MTD of 36 g/m 2 in this group of high-risk children or refractory ANLL. Furthermore, this is the first description of the tolerability of Ara-C given at the MTD of 36 g/m 2 in a with relapsed, refractory or secondary leukemias because available preclinical and clinical data suggest a strong dosepediatric population. Finally, this report is the first to indicate that a total dose of 1200 mg/m 2 of etoposide may safely be response for Ara-C, and because the DLT of cerebellar ataxia for high-dose Ara-C is highly age-related.
given following Ara-C at the MTD of 36 g/m 2 . Reports of the benefits of high doses of etoposide as a part of preparative We utilized high doses of etoposide, rather than the more commonly used anthracyclines, 24 in combination with highregimens for BMT 53, 54 suggest that high doses of etoposide may have an important dose-effect in acute leukemias similar dose Ara-C for several reasons: (1) presumed resistance to anthracyclines in relapsed or refractory acute leukemia to that seen with Ara-C. Although preclinical and clinical data
